ATE420654T1 - Behandlung von muskeldystrophien und verwandter erkrankungen - Google Patents

Behandlung von muskeldystrophien und verwandter erkrankungen

Info

Publication number
ATE420654T1
ATE420654T1 AT02757182T AT02757182T ATE420654T1 AT E420654 T1 ATE420654 T1 AT E420654T1 AT 02757182 T AT02757182 T AT 02757182T AT 02757182 T AT02757182 T AT 02757182T AT E420654 T1 ATE420654 T1 AT E420654T1
Authority
AT
Austria
Prior art keywords
abnormal
treatment
related diseases
activity
diseases
Prior art date
Application number
AT02757182T
Other languages
English (en)
Inventor
Justin Fallon
Michael Rafii
Beth Mckechnie
Mark Bowe
Mary Lynn Mercado
Hiroki Hagiwara
Alison Amenta
Original Assignee
Univ Brown Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brown Res Found filed Critical Univ Brown Res Found
Application granted granted Critical
Publication of ATE420654T1 publication Critical patent/ATE420654T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02757182T 2001-08-15 2002-08-15 Behandlung von muskeldystrophien und verwandter erkrankungen ATE420654T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31255101P 2001-08-15 2001-08-15

Publications (1)

Publication Number Publication Date
ATE420654T1 true ATE420654T1 (de) 2009-01-15

Family

ID=23211978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02757182T ATE420654T1 (de) 2001-08-15 2002-08-15 Behandlung von muskeldystrophien und verwandter erkrankungen

Country Status (7)

Country Link
US (3) US7759314B2 (de)
EP (1) EP1423133B1 (de)
AT (1) ATE420654T1 (de)
AU (1) AU2002323217B2 (de)
CA (1) CA2455884C (de)
DE (1) DE60230877D1 (de)
WO (1) WO2003015615A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
US6864236B1 (en) 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
AU2002323217B2 (en) 2001-08-15 2008-04-10 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
HUE044239T2 (hu) * 2008-03-27 2019-10-28 Purdue Research Foundation Kollagén-kötõ szintetikus peptidoglikánok, elõállításuk és alkalmazási eljárásaik
US20110224128A1 (en) * 2009-04-13 2011-09-15 Anne Whalen Methods and compositions for treatment of muscular dystrophy
KR100983182B1 (ko) * 2009-08-14 2010-09-20 (주)엔솔테크 신규 펩타이드 및 그 용도
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
AU2011256256B2 (en) 2010-05-17 2015-12-17 Brown University Biglycan mutants and related therapeutics and methods of use
EP3026432A3 (de) 2010-12-27 2016-07-27 Brown University Verfahren zur vorhersage der patientenreaktion auf eine behandlung mit biglycan
US9217016B2 (en) 2011-05-24 2015-12-22 Symic Ip, Llc Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
EP2970509B1 (de) 2013-03-15 2020-05-13 Purdue Research Foundation Extrazelluläre matrix zur bindung synthetischer peptidglycane
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
EP3139949B1 (de) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Zusammensetzungen enthaltend ein vip-elp fusionsprotein zur verwendung in der behandlung von mukoviszidose
ES2822598T3 (es) 2015-02-09 2021-05-04 Phasebio Pharmaceuticals Inc Métodos y composiciones para tratar enfermedades y trastornos musculares
CN108463211B (zh) 2015-11-16 2022-09-27 全国儿童医院研究所 用于治疗肌联蛋白类肌病和其它肌联蛋白病变的材料和方法
WO2018067449A1 (en) * 2016-10-05 2018-04-12 Bio-Techne Corporation Methods and kits for assaying endoglycosidase activity
WO2019010484A2 (en) 2017-07-07 2019-01-10 Symic Ip, Llc SYNTHETIC BIOCONJUGATES
IL279789B2 (en) 2018-06-29 2026-04-01 Res Inst Nationwide Childrens Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A
US20220002438A1 (en) * 2018-09-10 2022-01-06 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) Musk inhibition
KR20210133242A (ko) 2019-02-26 2021-11-05 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 B-사르코글리칸의 아데노 관련 바이러스 벡터 전달 및 근이영양증의 치료
AU2020257262B2 (en) 2019-04-18 2026-06-04 Brown University Neurogenesis
US20230304012A1 (en) * 2019-10-16 2023-09-28 Brown University Muscle regeneration and growth
EP4772533A1 (de) * 2023-08-28 2026-07-08 Kexing Medical Device Co., Ltd. Rekombinantes humanisiertes triple-helix-kollagen vom typ iii, herstellungsverfahren dafür und verwendung davon

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5340934A (en) 1989-11-03 1994-08-23 The United States Of Americas As Represented By The Secretary Of Health & Human Services CDNA sequences of human bone matrix proteins
JP3854307B2 (ja) 1991-12-04 2006-12-06 ザ バーナム インスティテュート 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
US5955265A (en) 1992-02-06 1999-09-21 Massachusetts Institute Of Technology DNA sequence encoding the myotonic dystrophy gene and uses thereof
DE69433970T2 (de) 1993-08-10 2005-08-11 W.L. Gore & Associates, Inc., Newark Zelleinkapselungsvorrichtung
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
WO1995013298A1 (en) 1993-11-10 1995-05-18 Worcester Foundation For Experimental Biology Agrin receptor
AU6926194A (en) 1994-05-09 1995-11-29 Boehringer Mannheim Gmbh Use of chondroitin sulphate proteoglycans for protection of neurons
US5882868A (en) 1997-04-14 1999-03-16 The Nemours Foundation Method of diagnosing spinal muscular atrophy
EP1161258A1 (de) 1999-03-17 2001-12-12 EntreMed, Inc. Zusammensetzungen und verfahrungen von ldl rezeptor oder dergleichen liganden zur behandlung von krebs und angiogenischen erkrankungen
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
WO2001036475A2 (en) * 1999-11-18 2001-05-25 Brown University Research Foundation Biglycan and related therapeutics and methods of use
US6864236B1 (en) 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
AU2002323217B2 (en) 2001-08-15 2008-04-10 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
WO2008100789A2 (en) 2007-02-16 2008-08-21 Benaroya Research Institute At Virginia Mason Compositions and methods for altering elastogenesis
AU2011256256B2 (en) 2010-05-17 2015-12-17 Brown University Biglycan mutants and related therapeutics and methods of use

Also Published As

Publication number Publication date
WO2003015615A3 (en) 2003-11-13
EP1423133B1 (de) 2009-01-14
WO2003015615A9 (en) 2003-08-07
US20050043221A1 (en) 2005-02-24
US20150182589A1 (en) 2015-07-02
EP1423133A2 (de) 2004-06-02
WO2003015615A2 (en) 2003-02-27
CA2455884C (en) 2015-09-22
US7759314B2 (en) 2010-07-20
CA2455884A1 (en) 2003-02-27
EP1423133A4 (de) 2006-03-01
DE60230877D1 (de) 2009-03-05
AU2002323217B2 (en) 2008-04-10
US8822418B2 (en) 2014-09-02
US20110053854A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
DE60230877D1 (de) Behandlung von muskeldystrophien und verwandter erkrankungen
DE60027762D1 (de) Diagnose und behandlung von arthritischen erkrankungen
DE602005019874D1 (de) Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1-rezeptors
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
NO20010446L (no) Substituert anilidforbindelser og metoder
ES2178668T4 (es) Naftilamidas como agentes del sistema nervioso central.
TR200103104T2 (tr) Glukortikoid alıcı modülatörleri
ATE443699T1 (de) Pyridine zur behandlung von verletztemsäugetiernervengewebe
DE69738613D1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
DE59810761D1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
ATE352311T1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
Monemi et al. Adverse changes in fibre type and myosin heavy chain compositions of human jaw muscle vs. limb muscle during ageing
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
ATE338142T1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
WO2003070195A3 (en) Biglycan and related therapeutics and methods of use
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
ATE232739T1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties